Daniel M. Junius - 28 Jul 2023 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role: Director
Signature: /s/ Lily J. Lu, Attorney-in-Fact for Daniel M. Junius
Issuer symbol: IDXX
Transactions as of: 28 Jul 2023
Net transactions value: +$7,739
Form type: 4
Filing time: 01 Aug 2023, 17:19:55 UTC
Previous filing: 22 May 2023
Next filing: 01 Nov 2023
SEC: View on sec.gov

Quoteable Key Fact

"Daniel M. Junius filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 01 Aug 2023."

Quick Takeaways

This page summarizes Daniel M. Junius's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 01 Aug 2023, 17:19.

What Changed

Previous filing in this sequence was filed on 22 May 2023.
Current net transaction value: +$7,739.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IDXX	Common Stock	Award	$7,739	+14	+0.47%	$552.78	3,009	28 Jul 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($7,500.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

Content

Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($7,500.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.